From Supertankers To Speedboats: Executives Make The Leap From Big Pharma To Start-Ups
Trade-Offs Include Faster Decision-Making, Greater Risk-Taking
Executive Summary
Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs.
You may also be interested in...
Ken Frazier Joins Former Merck & Co Colleagues At Eikon Therapeutics
Frazier has answered the call from Roger Perlmutter, his former head of R&D at Merck, to help the mysterious new biotech develop its platform.
Merck & Co.'s Barr To Lead Clinical Development After Baynes Departs For Eikon
Longtime R&D leader Roy Baynes is leaving Merck to become chief medical officer at the biotech start-up helmed by Merck's former R&D chief Roger Perlmutter.
Hal Barron To Depart GSK To Head Up New Biotech
As Barron departs for new rejuvenation-focused biotech Altos Labs, GSK will be under pressure to ensure its R&D can continue to produce green shoots.